PubMed Central (PMC) Search Page
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 1995 | 1 |
| 1999 | 2 |
| 2000 | 2 |
| 2002 | 2 |
| 2003 | 4 |
| 2004 | 1 |
| 2005 | 21 |
| 2006 | 41 |
| 2007 | 44 |
| 2008 | 277 |
| 2009 | 430 |
| 2010 | 325 |
| 2011 | 380 |
| 2012 | 338 |
| 2013 | 387 |
| 2014 | 351 |
| 2015 | 364 |
| 2016 | 379 |
| 2017 | 327 |
| 2018 | 364 |
| 2019 | 353 |
| 2020 | 337 |
| 2021 | 348 |
| 2022 | 357 |
| 2023 | 361 |
| 2024 | 360 |
| 2025 | 328 |
| 2026 | 262 |
-
Publication date
-
-
Publication stage
These filters represent the three primary types of content included in the PMC archive: 1) content published in a scholarly journal 2) peer-reviewed author manuscripts accepted for publication in a journal and 3) preprint versions of articles collected through the NIH Preprint Pilot, made public prior to peer review
-
-
Collections
The PMC Open Access Subset includes journal articles and preprints that are made available under license terms that allow reuse. Historical back issues refers to digitized content from print journals made available in PMC through the Biomedical Journal Digitization Projects.
-
"Clin Cancer Res"[Journal]
The embargo is the time during which the publisher retains exclusive rights to distribute articles. Those articles are made freely available on the PMC website after the embargo period has ended. Citations for articles under an embargo period will still display in the PMC results list by default. Choose “Exclude” to prevent embargoed articles from displaying in your results.
-
Brightline-1: When a Negative Trial Reveals Two Active Therapies.
- Shahnam A, Gounder MM.
- Clin Cancer Res. 2026 Oct 15;32(20):4511-4513. doi: 10.1158/1078-0432.CCR-26-2134.
- PMCID: PMC13669730
Shahnam A, et al.Clin Cancer Res. 2026.PMCID: PMC13669730 -
Rilvegostomig for Metastatic Non-Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study.
- Rohrberg KS, Brandão M, Castañón Álvarez E, Felip E, Gort E, Hiltermann TJN, Izumi H, Kim DW, Kim SW, Paz-Ares L, Solomon B, Smit EF, Wauters E, Yoshida T, Ayyoub A, Chen HA, Colebrook S, Hamidi NN, Kuziora M, Lim K, Achour I, Drachsler MW, Karanovic D, Liu N, Cho BC.
- Clin Cancer Res. 2026 Oct 15;32(20):4602-4611. doi: 10.1158/1078-0432.CCR-26-0333.
- PMCID: PMC13669723
Rohrberg KS, et al.Clin Cancer Res. 2026.PMCID: PMC13669723 -
Weight Loss Responses to Pharmacotherapy in Breast Cancer Survivors: Results from the Adaptive Nutrition and Exercise Weight Loss (A-NEW) Study.
- Sheng JY, Zahurak ML, Too F, Montanari A, Trost J, Lu M, Lee Y, Parida S, Blackford AL, Sharma D, Laudenslager M, Snyder C, Coughlin JW, Stearns V.
- Clin Cancer Res. 2026 Oct 15;32(20):4633-4642. doi: 10.1158/1078-0432.CCR-26-0270.
- PMCID: PMC13669726
Sheng JY, et al.Clin Cancer Res. 2026.PMCID: PMC13669726 -
Circulating Thymidine Kinase Activity Predicts Survival and Optimal Treatment Sequencing in BRAF-Mutated Metastatic Melanoma in the SECOMBIT Trial.
- Helgadottir H, Capone M, Ridolfi L, Zambelli A, Piccin L, Gogas H, Tucci M, Quaglino P, Del Vecchio M, Minisini AM, Spagnolo F, Rutkowski P, Ferraresi V, Arance A, Guida M, Maiello E, Lebbé C, Bulgarelli J, Chiarion Sileni V, Paone M, Melero I, Trojaniello C, Bergqvist M, Dummer R, Giannarelli D, Palmieri G, Ascierto PA.
- Clin Cancer Res. 2026 Oct 15;32(20):4592-4601. doi: 10.1158/1078-0432.CCR-26-1402.
- PMCID: PMC13669722
Helgadottir H, et al.Clin Cancer Res. 2026.PMCID: PMC13669722 -
Multicenter Phase I Study of Triapine in Combination with [177Lu]Lutetium-Dotatate in Patients with Well-Differentiated Neuroendocrine Tumors (ETCTN 10388).
- Chauhan A, Weiss HL, Kunos C, Jayswal R, Konda B, Soares HP, Li D, Halfdanarson TR, Mulcahy MF, Jacene HA, Khurana A, Modak R, Yan D, Beumer JH, Christner SM, Wu PI, Das B, Rubinstein LV, Gore SD, Ivy SP, Kohn EC, Carson WE, Anthony LB, Arnold SM.
- Clin Cancer Res. 2026 Oct 15;32(20):4612-4621. doi: 10.1158/1078-0432.CCR-26-0686.
- PMCID: PMC13669721
Chauhan A, et al.Clin Cancer Res. 2026.PMCID: PMC13669721 -
A Phase II Multicenter Trial of Rucaparib and Nivolumab as Maintenance Therapy in Patients with Advanced Biliary Tract Cancer: BilT-02.
- Mohan A, Griffith KA, Goff LW, Crysler O, Enzler T, Cardin DB, Gunchick V, Tsang AP, Dippman D, Young AS, Olivei AC, Mannan R, Rao A, Frankel TL, Kumar-Sinha C, Zalupski MM, Sahai V.
- Clin Cancer Res. 2026 Oct 15;32(20):4563-4570. doi: 10.1158/1078-0432.CCR-25-1114.
- PMCID: PMC13669724
Mohan A, et al.Clin Cancer Res. 2026.PMCID: PMC13669724 -
AI-Based Pathology Classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial.
- Medina S, Tokuyama N, Putcha V, Pathak T, Fu P, Thomas H, Subhash VV, Yip S, Lin HM, Horvath LG, Kench JG, Zhang A, Stockler MR, Joshua AM, Azad A, Oakes SR, Davis ID, Sweeney CJ, Madabhushi A.
- Clin Cancer Res. 2026 Oct 15;32(20):4742-4753. doi: 10.1158/1078-0432.CCR-26-0871.
- PMCID: PMC13669734
Medina S, et al.Clin Cancer Res. 2026.PMCID: PMC13669734 -
Brigimadlin versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety, and Translational Data from Brightline-1, a Randomized Phase II/III Trial.
- Schöffski P, Sanfilippo R, Martín-Broto J, Kawai A, Desai J, LoRusso P, Maki RG, Jones RL, Blay JY, Smrke A, Abdul Razak A, Italiano A, Sebio A, Bahleda R, Lee YC, van der Graaf WTA, Zhang X, Biyukov T, Teufel M, Fu E, Lahmar M, Wagner AJ.
- Clin Cancer Res. 2026 Oct 15;32(20):4538-4551. doi: 10.1158/1078-0432.CCR-26-0509.
- PMCID: PMC13669732
Schöffski P, et al.Clin Cancer Res. 2026.PMCID: PMC13669732 -
Clinical Implications of The Cancer Genome Atlas Molecular Classification System in Esophagogastric Cancer.
- Walch HS, Borpatragohain R, Jee J, Chatila W, Fong C, Maron SB, Ku GY, Ilson DH, Janjigian YY, Wu AJ, Shah P, Coit DG, Bains MS, Rusch VW, Park BJ, Bott MJ, Gray K, Jones DR, Berger M, Schultz N, Strong VE, Molena D, Sihag S.
- Clin Cancer Res. Author manuscript. 2025 May 15;31(10):1912-1921. doi: 10.1158/1078-0432.CCR-24-3473.
- PMCID: PMC13659750
Walch HS, et al.Clin Cancer Res. Author manuscript. 2025.PMCID: PMC13659750 -
Curation of the Pancreatic Ductal Adenocarcinoma Subset of the Cancer Genome Atlas Is Essential for Accurate Conclusions about Survival-Related Molecular Mechanisms.
- Peran I, Madhavan S, Byers SW, McCoy MD.
- Clin Cancer Res. Author manuscript. 2018 May 8;24(16):3813-3819. doi: 10.1158/1078-0432.CCR-18-0290.
- PMCID: PMC13652106
Peran I, et al.Clin Cancer Res. Author manuscript. 2018.PMCID: PMC13652106